...
首页> 外文期刊>Urology Annals >Clinical features and outcomes of nontransitional cell carcinomas of the urinary bladder: Analysis of 125 cases
【24h】

Clinical features and outcomes of nontransitional cell carcinomas of the urinary bladder: Analysis of 125 cases

机译:非膀胱移行细胞癌的临床特点和预后:附125例分析

获取原文
           

摘要

Objectives: The aim was to evaluate pathologic diagnosis, treatment and prognosis of 125 patients with nontransitional cell carcinoma of the urinary bladder. Materials and Methods: A total of 3590 patients with bladder tumors operated in our clinic between September 1998 and May 2013 were retrospectively evaluated. A total of 125 patients (107 men and 18 women) with nontransitional cell bladder cancer, confirmed by histopathology, were included in this study. The patients' characteristics, including age, gender, smoking history, tumor size, and localization, histological types, pathological tumor stages, treatment modalities, and survival rates were all recorded. Results: Of these tumors, 47 (37.6%) were adenocarcinoma (AC), 42 (33.6%) were squamous cell carcinoma (SCC), 23 (18.4%) were undifferentiated carcinoma (UC), 13 (10.4%) were other types of bladder carcinoma. Sixty-three (50.4%) patients had undergone radical cystectomy and pelvic lymphadenectomy ± adjuvant treatment (chemotherapy [CT]/radiotherapy) and 52 (41.6%) patients received radiotherapy ± CT. The median survival time of patients with AC and SCC were significantly higher than patients with UC (AC vs UC, P = 0.001; SCC vs UC, P = 0.000; AC vs. SCC, P = 0.219). Median survival time was significantly higher in radical cystectomy ± adjuvant treatment group (P Conclusion: Prognosis of urinary bladder tumors was directly related to histological type and stage of the tumor. CT or radiotherapy has limited response rates. Early radical cystectomy should be performed to improve prognosis.
机译:目的:旨在评估125例膀胱非过渡性细胞癌的病理诊断,治疗和预后。资料与方法:回顾性分析1998年9月至2013年5月间在我们诊所手术的3590例膀胱肿瘤患者。经组织病理学证实的总共125例非过渡性膀胱癌患者(107例男性和18例女性)被纳入本研究。记录患者的特征,包括年龄,性别,吸烟史,肿瘤大小和位置,组织学类型,病理性肿瘤分期,治疗方式和生存率。结果:在这些肿瘤中,腺癌(AC)47例(37.6%),鳞癌(SCC)42例(33.6%),未分化癌(UC)23例(18.4%),其他类型13例(10.4%)膀胱癌。接受根治性膀胱切除术和盆腔淋巴结清扫术±辅助治疗(化学疗法[CT] /放疗)的患者为63例(50.4%),接受放射治疗±CT的患者为52例(41.6%)。 AC和SCC患者的中位生存时间显着高于UC患者(AC vs UC,P = 0.001; SCC vs UC,P = 0.000; AC vs. SCC,P = 0.219)。根治性膀胱切除术±辅助治疗组的中位生存时间明显更长(P结论:膀胱肿瘤的预后与肿瘤的组织学类型和分期直接相关。CT或放疗的反应率有限。应早期进行根治性膀胱切除术以改善预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号